other material
confidence high
sentiment positive
materiality 0.75
Crinetics reports positive Phase 2 results for paltusotine in carcinoid syndrome
Crinetics Pharmaceuticals, Inc.
- Phase 2 trial: 63% reduction in mean flushing frequency (p<0.0001) for patients with >1/day at baseline.
- 60% reduction in mean excess bowel movements (p=0.02) for patients with >3/day at baseline; 61% reduction in flushing severity (p<0.0001).
- Paltusotine generally well-tolerated; no treatment-related severe or serious AEs; common AEs included diarrhea, abdominal pain, nausea, headache.
- Company plans to engage FDA to align on Phase 3 design; expects to initiate Phase 3 program by end of 2024.